Literature DB >> 2659714

Natural killer cell function in patients with acquired immunodeficiency syndrome and related diseases.

B G Brenner1, A Dascal, R G Margolese, M A Wainberg.   

Abstract

This review describes current knowledge of changes in natural killer (NK) cell function in acquired immunodeficiency syndrome (AIDS)-related disorders, vis-à-vis associated abnormalities in NK cytolytic function, NK cell subset distribution, NK cytopathology, and lymphokine regulation. NK cells, which are closely associated with large granular lymphocytes, are spontaneously cytotoxic to tumor and virally infected targets. As such, they may play a role in natural resistance to human immunodeficiency virus type 1 (HIV-1)-associated disorders and other opportunistic infections. Yet, peripheral blood NK activity is frequently reduced in patients with HIV-1-induced disease. NK cells are heterogeneous both with respect to their expression of serologically defined membrane antigens and functional activity. In AIDS-related syndromes, there appears to be a diminution of the NK pool (CD16+ cells) involved in cytolytic function, while there is an elevation of the NK pool that coexpresses NK (Leu 7+) and T (CD8+) cell markers, which show little or no involvement in cytolytic function. The impairment of in vitro NK function is not associated with a reduced frequency of lytic conjugates of effectors and target cells nor with the recycling capacity of these effector cells but rather is associated with defects in the NK cell lytic machinery following formation of such conjugates. NK cells in AIDS patients show an impairment in effector cell microtubule rearrangement following target cell interaction. The causes of NK cell dysfunction in AIDS-related disorders remain unknown. NK cells do not appear to express the CD4 epitope of the HIV receptor, nor have they been demonstrated to be susceptible to infection by HIV-1. There appears to be a preponderance of immature NK cells and a lymphokine imbalance in patients with HIV-1 associated disease. Interleukin-2 can partially restore diminished in vitro NK function. Elucidation of the involvement of the NK compartment in natural resistance to HIV-1 merits further investigation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2659714     DOI: 10.1002/jlb.46.1.75

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  21 in total

Review 1.  P glycoprotein in human immunodeficiency virus type 1 infection and therapy.

Authors:  Sanjay U C Sankatsing; Jos H Beijnen; Alfred H Schinkel; Joep M A Lange; Jan M Prins
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

2.  Innate immune natural killer cells and their role in HIV and SIV infection.

Authors:  Pavel Bostik; Yoshiaki Takahashi; Ann E Mayne; Aftab A Ansari
Journal:  HIV Ther       Date:  2010-07-01

3.  Reversal of human immunodeficiency virus type 1 protein-induced inhibition of natural killer cell activity by alpha interferon and interleukin-2.

Authors:  M P Nair; S A Schwartz
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

4.  Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection.

Authors:  R Ahmad; S T Sindhu; E Toma; R Morisset; J Vincelette; J Menezes; A Ahmad
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

5.  In vitro infection of natural killer cells with different human immunodeficiency virus type 1 isolates.

Authors:  J Chehimi; S Bandyopadhyay; K Prakash; B Perussia; N F Hassan; H Kawashima; D Campbell; J Kornbluth; S E Starr
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

6.  Evidence for circulating activated cytotoxic T cells in HIV-infected subjects before the onset of opportunistic infections.

Authors:  G Vanham; L Kestens; P Gigase; R Colebunders; M Vandenbruaene; L Brijs; J L Ceuppens
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

7.  Changes in natural immunity during the course of HIV-1 infection.

Authors:  B G Brenner; C Gryllis; M Gornitsky; M A Wainberg
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

8.  Increased LAK activity against HIV-infected cell lines in HIV-1+ individuals.

Authors:  C Gryllis; M A Wainberg; Z Bentwich; M Gornitsky; B G Brenner
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

9.  Enhancement of natural killer cell activity in human immunodeficiency virus-infected subjects by in vitro treatment with biologic response modifier OK-432.

Authors:  X L Huang; Z Fan; T Murayama; C Rinaldo
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

Review 10.  NK cells in HIV-1 infection: evidence for their role in the control of HIV-1 infection.

Authors:  G Alter; M Altfeld
Journal:  J Intern Med       Date:  2009-01       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.